Table 4 Percentage of leukocyte populations and cell ratios in nAMD patients with CNV and RAP.
From: Alterations in Circulating Immune Cells in Neovascular Age-Related Macular Degeneration
Univariate analysis | Multivariate analysis (age and gender) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Variables | Controls (mean ± SD) n= 26 | CNV (mean ± SD) n= 66 | RAP (mean ± SD) n= 13 | P value CNV vs RAP 1 | P value CNV vs RAP vs controls 2 | P value Bonferroni post hoc test | P value CNV vs RAP vs controls 3 | Odds ratio | 95% confidence interval for odds ratio |
Cell subsets (FSC/SSC plot) | |||||||||
Lymphocytes (%) | 30.45 ± 7.82 | 27.13 ± 7.32 | 24.62 ± 6.36 | 0.254 | 0.047 | 0.1614 0.0645 | |||
Monocytes (%) | 7.28 ± 1.88 | 7.84 ± 2.38 | 8.44 ± 4.02 | 0.468 | 0.382 | ||||
Neutrophils (%) | 59.80 ± 8.73 | 63.28 ± 7.55 | 65.35 ± 8.01 | 0.373 | 0.075 | ||||
Neutrophil/Lymphocyte ratio | 2.16 ± 0.84 | 2.62 ± 1.17 | 2.87 ± 0.96 | 0.329 | 0.055 | ||||
Cell subsets (CD antigens) | |||||||||
CD14+ (%) | 7.35 ± 1.95 | 7.61 ± 2.05 | 8.45 ± 3.57 | 0.336 | 0.472 | ||||
CD4+ (%) | 12.21 ± 3.92 | 11.88 ± 4.75 | 10.77 ± 3.02 | 0.600 | 0.614 | ||||
CD8+ (%) | 5.86 ± 2.96 | 5.25 ± 3.66 | 4.69 ± 2.49 | 0.978 | 0.425 | ||||
CD19+ (%) | 3.41 ± 2.16 | 2.86 ± 1.37 | 2.19 ± 1.23 | 0.117 | 0.110 | ||||
CD56+ (%) | 3.27 ± 1.66 | 3.50 ± 2.16 | 3.39 ± 1.71 | 0.801 | 0.958 | ||||
CD11b+ (%) | 67.40 ± 9.00 | 72.00 ± 7.92 | 76.72 ± 5.42 | 0.082 | 0.007 | 0.0864 0.0095 | 0.046 4 0.033 5 | 1.07 1.15 | 1.00 ± 1.14 1.01 ± 1.30 |
CD16hiHLA-DR− Neutrophils (%) | 57.80 ± 9.05 | 62.92 ± 8.09 | 63.26 ± 7.77 | 0.888 | 0.025 | 0.0274 0.1665 | 0.0154 0.3045 | 1.08 1.05 | 1.01 ± 1.14 0.96 ± 1.15 |
CD16hiHLA-DR−/(CD4 + CD8) ratio | 3.51 ± 1.49 | 4.25 ± 1.92 | 4.51 ± 1.56 | 0.487 | 0.150 | ||||
CD16hiHLA-DR−/CD4 ratio | 5.34 ± 2.34 | 6.26 ± 2.94 | 6.40 ± 2.16 | 0.595 | 0.317 | ||||
CD16hiHLA-DR−/CD8 ratio | 13.80 ± 11.28 | 20.40 ± 18.82 | 17.00 ± 8.09 | 0.997 | 0.221 | ||||
CD16hiHLA-DR−/CD19 ratio | 25.69 ± 21.26 | 31.21 ± 27.79 | 45.60 ± 40.21 | 0.131 | 0.083 | ||||
CD16hiHLA-DR−/CD56 ratio | 22.41 ± 11.25 | 27.33 ± 23.06 | 23.06 ± 10.91 | 0.942 | 0.922 |